Bevacizumab Improves Survival in Metastatic Breast Cancer
Treatment with the combination of bevacizumab (Avastin) and chemotherapy improved progression-free survival (PFS) and overall survival (OS) in women with HER2-negative metastatic breast cancer, according to two phase III studies being presented at the 2014 ESMO Congress later this week.
http://www.onclive.com/conference-co...-Breast-Cancer |
All times are GMT -7. The time now is 05:00 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021